Il-15r Alpha Forms, Cells Expressing Il-15r Alpha Forms, And Therapeutic Uses Of Il-15r Alpha And Il-15/il-15r Alpha Complexes

  • Published: Aug 10, 2016
  • Earliest Priority: Oct 24 2012
  • Family: 18
  • Cited Works: 4
  • Cited by: 0
  • Cites: 2
  • Additional Info: Cited Works Published
Full-text?

The full document isn't yet available to us from the patent office, but we've found a related patent (family member) to use for our images and PDF.

Abstract

In one aspect, described herein are cyclical administration regimens for the administration of complexes comprising interleukin-15 (“IL-15”) covalently or noncovalently bound to IL-15 receptor alpha (“IL-15Ra”) to patients in order to enhance IL-15-mediated immune function. In one aspect, these cyclical administration regimens achieve plasma levels of IL-15 above basal levels while minimizing the toxicity associated with IL-15 administration. In a specific aspect, the cyclical administration regimens are useful in the prevention, treatment, and/or management of disorders in which enhancing IL-15-mediated function is beneficial, such as cancer, infectious diseases, immunodeficiencies and lymphopenia. Also described herein are purified soluble forms of IL-15Ra, cells that recombinantly express soluble forms of IL-15Ra, and compositions comprising complexes of IL-15 covalently or non-covalently bound to soluble forms of IL-15Ra. Further described herein are host cells that recombinantly express IL15-Ra derivatives comprising a mutation or deletion in the extracellular domain cleavage site, including IL-15Ra derivatives comprising the extracellular domain of IL-15Ra and a transmembrane domain of a heterologous molecule. In addition, described herein are methods for propagating, activating and/or differentiating IL-15 responsive cells, comprising co-culturing an IL-15 responsive cell(s) with a host cell(s) that recombinantly expresses IL-15Ra, and isolating the IL-15 responsive cell(s) from the host cell(s). The IL-15 responsive cells that are immune cells can be administered to prevent, treat and/or manage various disorders, including cancer, an infectious disease, an immunodeficiency and lymphopenia. Further, described herein are methods of enhancing IL-15-mediated immune function as well as methods for preventing, treating and/or managing disorders in which enhancing IL-15-mediated function is beneficial, such as cancer, in a subject, the methods comprising administering to the subject a host cell that recombinantly expresses an IL-15Ra described herein.


Claims

Information currently unavailable.

Family Member PDF
Family Member Preview
These are the images from a related family member, as the full document isn't yet available to us from the patent office.
Document History
  • Publication: Aug 10, 2016
  • Application: Oct 23, 2013
    EP EP 13849581 A
  • Priority: Oct 23, 2013
    US US 2013/0066424 W
  • Priority: May 6, 2013
    US US 201361820035 P
  • Priority: Oct 24, 2012
    US US 201261718169 P

Download Citation


Sign in to the Lens

Feedback